My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Obeticholic Acid (6-ECDCA; INT-747)
    Obeticholic Acid (6-ECDCA; INT-747)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1844
    CAS #: 459789-99-2Purity ≥98%

    Description: Obeticholic Acid (INT747; 6-ECDCA; 6-Ethylchenodeoxycholic acid; trade name Ocaliva), a novel derivative of cholic acid, is a potent, orally bioactive and selective agonist of farnesoid X receptor (FXR) with EC50 of 99 nM, and has anticholeretic and anti-inflammatory activities. It is a semi-synthetic analog of bile acid which has the chemical structure 6α-ethyl-chenodeoxycholic acid. Obeticholic Acid was approved in 2016 for use as a drug to treat primary biliary cholangitis, and is undergoing development for several other liver diseases and related disorders. It displays anticholeretic activity in a rat model of cholestasis. It inhibits vascular smooth muscle cell inflammation and migration as well as promotes adipocyte differentiation and regulates adipose cell function in vivo. 

    References: J Med Chem. 2002 Aug 15;45(17):3569-72; Am J Physiol Renal Physiol. 2009 Dec;297(6):F1587-96.

    Related CAS#: 863239-61-6 (Tauro-Obeticholic acid); 863239-60-5 (Glyco-Obeticholic acid)

    Customer Validation
    Top Publications Citing Invivochem Products
    • Citation of InvivoChem Vorinostat (V0255) by Nature 2021, 597(7874):119-125
    • Citation of InvivoChem Larotrectinib (V2599) by Cell. 2020 Nov 25;183(5):1202-1218.e25
    • Citation of InvivoChem Eprenetapopt (APR-246) by Science Adv 2022: 8, eabm9427.
    • Citation of InvivoChem 5-azacytidine (V0404) by Nature 2021, DOI: 10.1038/s41586-021-03850-3
    • Citation of InvivoChem Larotrectinib (V2599) by Cell 2020, doi: 10.1016/j.cell.2020.10.016.
    • Citation of InvivoChem Eprenetapopt (APR-246) by Science Adv 2022, doi: 10.1126/sciadv.abm9427.
    • Citation of InvivoChem Vorinostat/SAHA (V0255) by Nature 2021, DOI: 10.1038/s41586-021-03850-3.
    • Citation of InvivoChem Vitrakvi by Cell 2020, PMID: 33142117 PMCID: PMC8100789
    • Citation of InvivoChem APR-246 by Science Adv 2022, PMID: 36103522.
    • Citation of InvivoChem 5-azacytidine (V0404) by Nature 2021, DOI: 10.1038/s41586-021-03850-3.
    • Citation of InvivoChem LOXO-101 by Cell 2020, PMID: 33142117 PMCID: PMC8100789
    • Citation of InvivoChem Eprenetapopt by Science Adv 2022, PMID: 36103522.
    • Citation of InvivoChem Vorinostat/SAHA (V0255) by Nature 2021, PMID: 34433969
    • Citation of InvivoChem  ARRY-470 by Cell 2020, PMID: 33142117 PMCID: PMC8100789
    • Citation of InvivoChem 5-azacytidine (V0404) by Nature 2021, PMID: 34433969
    • Citation of InvivoChem BMH-21 (V1435) by Cell Stem Cell 2020, 26(6): 845-861.e12.
    • Citation of InvivoChem Eprenetapopt (APR-246) by Science Adv 2022, doi: 10.1126/sciadv.abm9427.
    • Citation of InvivoChem 5-azacytidine (V0404) by Nature 2021, DOI: 10.1038/s41586-021-03850-3.
    • Citation of InvivoChem V33339 Lys-SMCC-DM1 by PNAS Nexus 2022, pgac063, https://academic.oup.com/pna
    • Citation of InvivoChem 5-azacytidine by Nature 2021, PMID: 34433969
    • Citation of InvivoChem Ruxolitinib/Filgotinib/BMS-911543/Decernotinib by J Allergy Clin Immunol 2020
    • Citation of InvivoChem LGK974 /WNT974 (V1353) by  Cancer Cell 2021 Apr 12;39(4):529-547.e7.
    • Citation of InvivoChem V1386 Napabucasin (BBI-608) by J Exp Clin Cancer Res 2021 Oct 13;40(1):319.
    • Citation of InvivoChem 5-azacytidine (V0404) by Nature 2021, DOI: 10.1038/s41586-021-03850-3.
    • Citation of InvivoChem Epacadostat/INCB024360 (V0942) by Cancer Discov 2022: 12(4):1106-1127.
    • Citation of InvivoChem S63845 (V2797) by Cell Death and Disease 2020, 11:316.
    • Citation of InvivoChem BMS-582949 (V2668) by Cells 2020, 9(6):1472.
    • Citation of InvivoChem Apiin (V4467) by J Med Chem 2020, 63(15):8338-8358.
    • Citation of InvivoChem V0001 venetoclax by WO2021231323A1
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)420.63
    FormulaC26H44O4
    CAS No.459789-99-2
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 84 mg/mL (199.7 mM)
    Water: <1 mg/mL
    Ethanol: 84 mg/mL (199.7 mM)
    SMILES CodeC[[email protected]@H]([[email protected]]1CC[[email protected]@]2([H])[[email protected]]3([H])[[email protected]](O)[[email protected]](CC)[[email protected]]4([H])C[[email protected]](O)CC[[email protected]]4(C)[[email protected]@]3([H])CC[[email protected]]12C)CCC(O)=O
    SynonymsINT-747, 6-ECDCA; 6-Ethylchenodeoxycholic acid; Obeticholic acid; INT 747; INT747; Ocaliva.


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: Obeticholic Acid (also known as INT747; 6-ECDCA), a novel derivative of cholic acid, is a potent and selective agonist  of farnesoid X receptor (FXR) with EC50 of 99 nM. It is a semi-synthetic analog of bile acid which has the chemical structure 6α-ethyl-chenodeoxycholic acid. Obeticholic Acid is used as a drug to treat primary biliary cholangitis, and is undergoing development for several other liver diseases and related disorders.


    Kinase Assay: INT-747 is a potent and selective farnesoid X receptor (FXR) agonist with an EC50 of 99 nM.


    Cell Assay: 6-ECDCA increases the expression of FXR-regulated genes in rat hepatocytes. INT-747 reduces expression of liver JNK-1 and JNK-2. INT-747 (256 μg/mL) shows complete inhibition of bacterial growth in all strains tested. Intestinal permeability remains unaffected after INT-747-addition to an IFN-γ-exposed intestinal epithelium of Caco-2 cells.

    In VivoAdministration of LCA and its conjugates to rodents causes intrahepatic cholestasis,a pathogenic state characterized by decreased bile flow and the accumulation of bile constituents in the liver and blood. In DMH (dimethyldydrazine)-induced murine carcinogenesis model, LCA suppresses apoptosis almost completely in premalignant colon. LCA.
    Animal modelRat cholestasis model
    Formulation & DosageDissolved in saline; 7 μmol/kg/min;  Infused at the right jugular vein using PE-50 polyethylene tubing
    ReferencesJ Med Chem. 2002 Aug 15;45(17):3569-72; Am J Physiol Renal Physiol. 2009 Dec;297(6):F1587-96.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    Obeticholic Acid

    INT-747 treatment improves proteinuria and ameliorates renal structural changes in WD-fed DBA mice.Am J Physiol Renal Physiol. 2009 Dec;297(6):F1587-96.
     

    Obeticholic Acid

    INT-747 treatment promotes antifibrotic effects. Am J Physiol Renal Physiol. 2009 Dec;297(6):F1587-96.


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?